2014

FDA intends to look for evidence that the 'major statement' of drug risks as currently implemented in DTC TV ads is often too long and 'may result in reduced consumer comprehension, minimization of important risk information and, potentially, therapeutic noncompliance due to fear of side effects.'

According to Lea Katsanis, PhD, Marketing Professor at Concordia University's John Molson School of Business, developing a strong brand personality is an important way that pharmaceutical marketers can increase brand loyalty, brand trust, and ultimately brand equity.

Welcome to Volume 13, Issue #2 (February 2014) of Pharma Marketing News.

Welcome to Volume 13, Issue #1 (January 2014) of Pharma Marketing News.

This articles summarizes some major points made in a presentation by Carolyn Gauntlett, Senior Innovation Consultant with IMS Health, titled 'How to Make Sure You're Getting the Most Out of Your mHealth App Development.'

Every year Pharmaguy reviews the images that appeared on Pharma Marketing Blog and picks his favorites. 2013 is no exception.

This article includes insights on content marketing from pharma experts including Thibaud Guymard, Digital Marketing Manager at MSD France. Guymard has broad experience with pharma content marketing, including roles as co-creator of the Digital Health Think Tank and as an Advertising Manager at Saatchi & Saatchi Health. Guymard also assisted in developing the Pharma Content Marketing Webinar organized by Kakushin Webinars.

One example of how pharma companies can use infographics to educate their stakeholders is the Epilepsy Foundation/Lundbeck nationwide initiative to bring information about managing seizures to people living with epilepsy and their families. This article discusses how Centric Infographics worked with the Foundation to create the infographic system at the center of this successful campaign.

A Public Affairs Specialist at FDA's Center for Drug Evaluation and Research (CDER) confirmed to several reporters that this guidance is actually PART of the long-awaited guidance that was promised after the November, 2009 public hearing and required by section 1121 of the Prescription Drug User Fee Act (PDUFA).